FDA Approved: BESPONSA — Original Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)

View source ↗

Summary

FDA approved BESPONSA (inotuzumab ozogamicin) under an original application for adults with relapsed or refractory CD22-positive B-cell precursor acute lymphobl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Besponsa (inotuzumab ozogamicin)

Snippet

ORIG AP for BESPONSA (INOTUZUMAB OZOGAMICIN)